The Physical Driving Forces of Conformational Transition for TTR 91–96 with Proline Mutations
Journal of Chemical Information and Modeling · 25.11.2024 · 64 (22) · 8604-8615
DOI: 10.1021/acs.jcim.4c01464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, online erschienen am 08.11.2024. Verfasst von Yuanming Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Mathematics and Physics, Shanghai University of Electric Power, Shanghai 200090, China. Hauptthemen laut MEDLINE: Molecular Dynamics Simulation, Prealbumin, Mutation, Proline. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Mathematics and Physics, Shanghai University of Electric Power, Shanghai 200090, China.
- The Research Center of Chiral Drugs, Shanghai Frontiers Science Center for TCM Chemical Biology, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shangh…
ORCID-Profile: Yanyan Zhu, Huiyu Li
Zitieren
APA
Cao, Y., Xia, P., Zhu, Y., Zhao, Q., & Li, H. (2024). The Physical Driving Forces of Conformational Transition for TTR 91–96 with Proline Mutations. Journal of Chemical Information and Modeling, 64(22), 8604-8615. https://doi.org/10.1021/acs.jcim.4c01464
Vancouver
Cao Y, Xia P, Zhu Y, Zhao Q, Li H. The Physical Driving Forces of Conformational Transition for TTR 91–96 with Proline Mutations. Journal of Chemical Information and Modeling. 2024;64(22):8604-8615. doi:10.1021/acs.jcim.4c01464
BibTeX
@article{Cao2024,
author = {Cao, Yuanming and Xia, Pengxuan and Zhu, Yanyan and Zhao, Qingjie and Li, Huiyu},
title = {The Physical Driving Forces of Conformational Transition for TTR 91–96 with Proline Mutations},
journal = {Journal of Chemical Information and Modeling},
year = {2024},
volume = {64},
number = {22},
pages = {8604--8615},
doi = {10.1021/acs.jcim.4c01464}
}
EUVIMED